Georg Andreas Gundersen is CEO of Amicoat. Gundersen brings broad experience from both medicine, science and business. He spent six years at McKinsey & Company before joining Amicoat. He holds an MD and a PhD in Neuroscience from the University of Oslo.
Dr. Svendsen brings extensive research experience in medical biochemistry, synthetic organic chemistry and medicinal chemistry, specializing in antibacterial peptides. Dr. Svendsen received his PhD from the University of Tromsø, and has been visiting scientist at several distinguished international institutions, including in the laboratory of Professor K.B. Sharpless (Nobel Laureate, Chemistry, 2000) at Massachusetts Institute of Technology. He is a Professor of organic chemistry in the Faculty of Sciences at the University of Tromsø. Dr. Svendsen is also a co-founder and board member of Lytix Biopharma AS, a Norwegian pharmaceutical company focusing on cancer immunotherapy.
Mr. Axelsson received an education in Natural Science and presently serves as CEO in HotSwap AB (Jönköping, Sweden), a company working with product development for international industries. Axelsson brings broad experience with projects in medical equipment and instrumentation, plastics technology, and cost-effective manufacturing processes. Axelsson has long experience as project manager and as board member for various companies. As inventor Mr. Axelsson holds several patents.
Kjetil Vangsnes is CFO of Amicoat and is responsible for finance and administration. Vangsnes holds an MBA from INSEAD and an MSc from the Norwegian School of Economics. He brings with him a wide experience from industry, life science, oil services, and shipping. Vangsnes has 20 years experience as CFO in listed and non- listed companies. He has mainly worked in international settings and has experience from Norwegian, US (GE Healthcare) and French (Technip) group constellations. He has held overall financial responsibilities and has been a board member in companies in Norway and abroad.
